Literature DB >> 28466986

Targets for Heart Failure With Preserved Ejection Fraction.

S Nanayakkara1, D M Kaye1.   

Abstract

Heart failure (HF) with preserved ejection fraction (HFPEF) is responsible for half of all HF cases and will be the most common form of HF within the next 5 years. Previous studies of pharmacological agents in HFPEF have proved neutral or negative, in part due to phenotypic heterogeneity and complex underlying mechanisms. This review summarizes the key molecular and cellular pathways characterized in HFPEF as well as current and future therapies that target these mechanisms.
© 2017 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28466986     DOI： 10.1002/cpt.723

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


  4 in total

Review 1.  The Heart Failure with Preserved Ejection Fraction Conundrum-Redefining the Problem and Finding Common Ground?

Authors:  P Iyngkaran; M C Thomas; C Neil; M Jelinek; M Cooper; J D Horowitz; D L Hare; D M Kaye
Journal:  Curr Heart Fail Rep       Date:  2020-04

Review 2.  Common Comorbidities that Alter Heart Failure Prognosis - Shaping New Thinking for Practice.

Authors:  Pupalan Iyngkaran; Merlin Thomas; John D Horowitz; Paul Komesaroff; Michael Jelinek; David L Hare
Journal:  Curr Cardiol Rev       Date:  2021

3.  Machine learning can predict survival of patients with heart failure from serum creatinine and ejection fraction alone.

Authors:  Davide Chicco; Giuseppe Jurman
Journal:  BMC Med Inform Decis Mak       Date:  2020-02-03       Impact factor: 2.796

Review 4.  Interatrial Shunt Device for Heart Failure With Preserved Ejection Fraction.

Authors:  David M Kaye; Shane Nanayakkara
Journal:  Front Cardiovasc Med       Date:  2019-09-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.